SCHEMBL16245579

SCHEMBL16245579

COC(=O)CCn1cc(-n2nnc3cnc(Nc4cccc(OCCCNC(=O)OC(C)(C)C)c4)nc32)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITK Q08881 3/20 0.48
▸ EGFR P00533 2/20 0.48
▸ GSK3A P49840 5/20 0.45
▸ GSK3B P49841 5/20 0.45
▸ EIF2AK4 Q9P2K8 2/20 0.40
▸ AURKA O14965 3/20 0.40
▸ ABL1 P00519 1/20 0.38
▸ PDGFRB P09619 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ MAPK14 Q16539 1/20 0.38
▸ CYP1A2 P05177 4/20 0.38
▸ CLK4 Q9HAZ1 4/20 0.38
▸ CYP3A4 P08684 3/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16245615 0.94 ITK (0.49) ITKEGFRGSK3AGSK3BEIF2AK4
SCHEMBL16245530 0.92 GSK3A (0.53) ITKEGFRGSK3AGSK3BEIF2AK4
SCHEMBL17821171 0.90 GSK3A (0.52) ITKEGFRGSK3AGSK3BEIF2AK4
SCHEMBL16245915 0.86 GSK3A (0.52) ITKEGFRGSK3AGSK3BEIF2AK4
SCHEMBL16264886 0.85 GSK3A (0.48) GSK3AGSK3BEIF2AK4AURKAABL1
SCHEMBL16245568 0.84 GSK3A (0.51) ITKGSK3AGSK3BEIF2AK4AURKA
SCHEMBL16245750 0.83 GSK3A (0.53) ITKEGFRGSK3AGSK3BEIF2AK4
SCHEMBL16245571 0.82 ITK (0.51) ITKEGFRGSK3AGSK3BEIF2AK4
SCHEMBL17821182 0.82 GSK3A (0.51) ITKEGFRGSK3AGSK3BEIF2AK4
SCHEMBL18869177 0.82 GSK3A (0.47) ITKEGFRGSK3AGSK3BEIF2AK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
EP-2994471-A1 MACROCYCLES AS KINASE INHIBITORS Merck Patent GmbH (DE) 2016-03-16 — — EP disclosed
WO-2014180524-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS EIF2AK4, CDK2, CDK1 ITK 1468/4885EGFR 1412/4885GSK3A 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback